<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117023</url>
  </required_header>
  <id_info>
    <org_study_id>2017NLY002</org_study_id>
    <nct_id>NCT03117023</nct_id>
  </id_info>
  <brief_title>The Addition of Dexmedetomidine on Postoperative Sleep for Middle-aged and Elderly Patients With Gastric Cancer</brief_title>
  <official_title>The Addition of Dexmedetomidine on Postoperative Sleep for Middle-aged and Elderly Patients With Gastric Cancer: A Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effect of Dexmedetomidine for treatment of sleep
      deprivation, pain relief and postoperative recovery on middle-aged and elderly Patients with
      Gastric Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized to receive sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h (DEX
      group) or sufentanil 0.05ug/kg/h + saline (control group) for 48h. The primary outcome was
      the total sleep time during the first three days after surgery. The secondary outcomes
      included pain score, daily sufentanil consumption, time to functional recovery, length of
      hospital stay and side effects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sleep time</measure>
    <time_frame>during the first three days after surgery</time_frame>
    <description>total sleep time during the first three days after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain score</measure>
    <time_frame>during the first three days after surgery</time_frame>
    <description>pain score measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily sufentanil consumption</measure>
    <time_frame>during the first three days after surgery</time_frame>
    <description>daily sufentanil consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional recovery</measure>
    <time_frame>during the first three days after surgery</time_frame>
    <description>time to functional recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>during the first three days after surgery</time_frame>
    <description>length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>during the first three days after surgery</time_frame>
    <description>lethargy and mental sluggishness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sufentanil + dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>sufentanil + saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery</description>
    <arm_group_label>dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Elective gastric cancer operation Age ≧ 55 years ASA classification：I to III, BMI: 18-30
        kg/m2 without the history of gastrointestinal surgery the normal coagulation function -

        Exclusion Criteria:

        the history of gastrointestinal surgery Gastrostomy and jejunostomy sleep apnea syndrome or
        severe osahs Severe liver and heart dysfunction Severe mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Gao Tao</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>sleep deprivation</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>middle-aged and elderly patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

